The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin α activated): comparison between cord and adult plasma

Summary

The present study was performed to compare the anticoagulant efficiency of recombinant human activated protein C (rhAPC) in cord with that in adult plasma. RhAPC is a promising candidate to improve the outcome of severe sepsis. However, different anticoagulant efficiency of rhAPC in cord compared with adult plasma has to be expected due to physiological low plasma levels of tissue factor pathway inhibitor (TFPI) and antithrombin (AT) present in neonates, two inhibitors known to markedly influence the anticoagulant action of APC. Clot formation was induced in our experiments by addition of high (30 µM) or low (20 pM) amounts of lipidated tissue factor (TF). High amounts of TF are conventionally applied in standard clotting assays, whereas plasma activation with low amounts of TF probably better matches the conditions in vivo. We demonstrate that under low coagulant challenge increasing amounts of rhAPC (0.1 – 0.5 µg/ml final plasma concentration) dose-dependently prolonged clotting time and suppressed thrombin potential and prothrombin fragment 1 + 2 generation in both cord and adult plasma. The same was true for experiments performed under high coagulant challenge when 4 – 16 µg/ml of rhAPC were added. Whereby, cord plasma was significantly more susceptible to addition of rhAPC in the presence of high amounts of TF and adult plasma was significantly more susceptible to addition of rhAPC in the presence of low amounts of TF. We demonstrate that increased anticoagulant efficiency of rhAPC in adult plasma under low coagulant challenge is attributable to the physiological high levels of TFPI and AT present in adults.

Keywords

Recombinant human activated protein C - tissue factor pathway inhibitor - antithrombin - tissue factor - thrombin potential - cord and adult plasma

• References

• 1 Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
• 2 Hartman DL, Bernard GR, Helterbrand JD. et al. Recombinant human activated protein C (rhαPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Med 1998; 24 (Suppl. 01) S77.
• 3 Rawicz M, Sitkowska B, Rudzinska I. et al. Recombinant human activated protein C for severe sepsis in a neonate. Med Sci Monit 2002; 08: CS90-94.
• 4 Mann KG, Brummel K, Butenas S. What is all that thrombin for?. J Thromb Haemost 2003; 01: 1504-14.
• 5 Suzuki K, Stenflo J, Dahlbäck B. et al. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983; 258: 1914-20.
• 6 Fulcher CA, Gardiner JE, Griffin JH. et al. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63: 486-9.
• 7 Marlar RW, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-72.
• 8 Dahlbäck B, Villoutreix BO. Molecular recognition in the protein C anticoagulant pathway. J Thromb Haemost 2003; 01: 1525-34.
• 9 Glasscock LN, Gerlitz B, Cooper ST. et al. Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by alpha (1)-antitrypsin. Biochim Biophys Acta 2003; 1649: 106-17.
• 10 Scully MF, Toh CH, Hoogendoorn H. et al. Activation of Protein C and its distribution between it’s inhibitors, protein C inhibitor, a1-antitrypsin and a2-macroglobulin, in patients with DIC. Thromb Haemost 1993; 69: 448-53.
• 11 Hoogendoorn H, Toh CH, Nesheim ME. et al. Alpha 2-macroglobulin binds and inhibits activated protein C. Blood 1991; 78: 2283-90.
• 12 Cvirn G, Gallistl S, Muntean W. Alpha-2-macroglobulin inhibits the anticoagulant action of activated protein C in cord and adult plasma. Haemostasis 2001; 31: 1-11.
• 13 Van’t Veer C, Golden NJ, Kalafatis M. et al. Inhibitory mechanism of the protein C pathway on tissue factor-activated thrombin generation. J Biol Chem 1997; 272: 7983-94.
• 14 Cvirn G, Gallistl S, Rehak T. et al. Elevated thrombin-forming capacity of tissue factoractivated cord compared with adult plasma. J Thromb Haemost 2003; 01: 1785-90.
• 15 Andrew M, Paes B, Milner R. et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-72.
• 16 Reverdiau-Moalic P, Delahousse B, Body G. et al. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996; 88: 900-6.
• 17 Cvirn G, Gallistl Leschnik B. et al. Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in the neonate. J Thromb Haemost 2003; 01: 263-8.
• 18 Andrew M, Schmidt B, Mitchell L. et al. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990; 63: 27-30.
• 19 Butenas S, Van’t Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94: 2169-78.
• 20 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance and regulation. Biochemistry 1991; 30: 10363-70.
• 21 Rijkers DT, Wielders SJ, Beguin S. et al. Prevention of the influence of fibrin and alpha 2-macroglobulin in the continuous measurement of the thrombin potential: Implications for an endpoint determination of the optical density. Thromb Res 1998; 89: 161-9.
• 22 Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
• 23 Wielders S, Mukherjee M, Michiels J. et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
• 24 Hemker HC, Wielders S, Kessels H. et al. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
• 25 Schneider DM, von Tempelhoff GF, Herrle B. et al. Maternal and cord blood hemostasis at delivery. J Perinat Med 1997; 25: 55-61.
• 26 Reverdiau-Moalic P, Delahousse B, Body G. et al. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996; 88: 900-6.
• 27 Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89: 9-12.
• 28 Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-21.
• 29 Adams TE, Everse SJ, Mann KG. Predicting the pharmacology of thrombin inhibitors. J Thromb Haemost 2003; 01: 1024-7.
• 30 Smirnov MD, Safa O, Esmon NL. et al. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 1999; 94: 3839-46.
• 31 Muntean W, Danda M. Thrombin-Antithrombin III complex and D-dimer in neonates: Signs of thrombin generation during birth. In: Perinatal Thrombosis and Haemostasis. Suzuki S, Hathaway WE, Bonnar J, Sutor AH. eds. Tokyo: Springer; 1989: 57-64.
• 32 Monagle P, Ignjatovic V, Barnes C. et al. Reference ranges for hemostatic parameters in children. J Thromb Haemost 2003; (Suppl. 01) P0076.